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Adam A. Markovitz , Rob G. Holleman, Timothy P. Hofer,
Eve A. Kerr, Mandi L. Klamerus, and Jeremy B. Sussman
Objective. To compare the effects of two sequential policy changes—the addition of a
high-potency statin to the Department of Veterans Affairs (VA) formulary and the
release of the American College of Cardiology/American Heart Association (ACC/
AHA) cholesterol guidelines—onVA provider prescribing.
Data Sources/Study Setting. Retrospective analysis of 1,100,682 VA patients,
2011–2016.
Study Design. Interrupted time-series analysis of changes in prescribing of moderate-
to-high-intensity statins among high-risk patients and across high-risk subgroups. We
also assessed changes in prescribing of atorvastatin and other statin drugs. We esti-
mated marginal effects (ME) of formulary and guideline changes by comparing pre-
dicted and observed statin use.
Data Collection/ExtractionMethods. Data fromVACorporate DataWarehouse.
Principal Findings. The use of moderate-to-high-intensity statins increased by 2
percentage points following the formulary change (ME, 2.4, 95% confidence interval
[CI], 2.2 to 2.6) and less than 1 percentage point following the guideline change (ME,
0.8, 95% CI, 0.6 to 0.9). The formulary change led to approximately a 12 percentage-
point increase in the use of moderate-to-high-intensity atorvastatin (ME, 11.5, 95% CI,
11.3 to 11.6). The relatively greater provider response to the formulary change
occurred across all patient subgroups.
Conclusions. Addition of a high-potency statin to formulary affected provider pre-
scribing more than the ACC/AHA guidelines.
Key Words. Veterans Affairs, quality of care, cardiovascular disease, provider
interventions, pharmaceuticals
Cholesterol-lowering statin drugs are among the most important tools in med-
icine for lowering the rates of cardiovascular disease. In spite of this, the qual-
ity and effectiveness of statin prescribing are uneven (Kuklina, Yoon, and
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Health Services Research
Keenan 2009; Arnold et al. 2011; Maddox et al. 2014; Mozaffarian et al.
2016). Developing health system-level interventions to improve prescribing
has been a primary goal of the movement to improve quality of care for dec-
ades (Institute of Medicine 2001). Because of the central role played by provi-
ders in prescribing medications, many of these interventions have targeted
providers prescribing behaviors, including formulary restrictions, prescribing
targets, and clinical practice guidelines. Yet evidence on the effectiveness of
interventions targeting provider prescribing is mixed (O’Malley et al. 2006;
Francke et al. 2008; Lee et al. 2015; Rashidian et al. 2015). Previous investiga-
tions suggest that clinical practice guidelines are variably effective (Cabana
et al. 1999; Fischer and Avorn 2004; Hysong, Best, and Pugh 2007; Francke
et al. 2008). Some suggest that administrative or regulatory policies such as
formulary restrictions or Food and Drug Administration (FDA) guidance may
have greater influence on providers (Huskamp, Epstein, and Blumenthal
2003; Dorsey et al. 2010; Dusetzina et al. 2012). Nonetheless, there are little
data that allow for any kind of direct comparison of these policies.
The release of the 2013 American Heart Association/American College
of Cardiology (ACC/AHA) cholesterol treatment guidelines (Stone et al.
2014a) provides an ideal opportunity to examine the potential effects of clini-
cal practice guidelines on provider behavior. The ACC/AHA guideline fun-
damentally reshaped cholesterol treatment and simplified the task of
managing cardiovascular risk. The new guideline shifted focus away from the
previous 2004 guideline “treat-to-target” cholesterol approach (i.e., where sta-
tin intensities are altered until a specific cholesterol goal is reached) and
instead recommended prescribing moderate-to-high-intensity statin drugs to
all patients with high-cardiovascular risk. The ACC/AHA guideline gener-
ated an unusually intense degree of media coverage by abandoning choles-
terol targets, long an emphasis of providers and patients, and shifting focus to
cardiovascular risk (Herper 2013; Kolata 2013a, b; Ridker and Cook 2013).
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Given the authoritative nature of the ACC/AHA guideline, its relative sim-
plicity, and the considerable attention it captured, the ACC/AHA guideline
likely represents a “best case” scenario in the potential influence of guideline
changes on provider behavior.
However, other changes that could influence statin prescribing occurred
in the years prior to the ACC/AHA guideline. The entry of generic atorvas-
tatin, a higher potency statin than the previously recommended simvastatin,
in November 2011, promised to extend powerful cholesterol treatment
throughout the United States ( Jackevicius et al. 2012). Generic atorvastatin
was introduced soon after a June 2011 FDA “black box” warning about the
increased risk of muscle injury posed by high-dose simvastatin (Food and
Drug Administration 2011). By October 2012, the Department of Veterans
Affairs (VA), alongside other large health systems and insurers, had added
generic atorvastatin to formulary lists of approved drugs (Veterans Health
Administration 2012).
Despite the wide publicity of both the ACC/AHA cholesterol guideline
and the entry of generic atorvastatin, we know very little about how these poli-
cies affected statin provider behavior. We attempt to fill this gap by exploiting
the sequential introduction of two policies—the addition of atorvastatin to the
VA’s formulary in 2012 and the release of the ACC/AHA cholesterol guideli-
nes in 2013—to compare the effects of formularies and guidelines on prescrib-
ing behavior. We do so by performing interrupted time-series analyses on
national VA prescribing data, examining changes in the use of moderate-
to-high-intensity statins among high-risk patients. We also examine changes in
the use of specific statin drugs to further delineate the effects of the formulary
and guideline changes.
METHODS
Data
We constructed the study population using the VA Corporate Data Ware-
house, a comprehensive database that contains data on all patients seen in the
VA.
Study Population
We performed a retrospective open-cohort study. Our sample consisted of all
of active VA primary care patients between ages 40 and 75 who sought care
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between July 1, 2011, and June 30, 2016, and were statutorily exempt from
copayments due to meeting the VA Priority Group 1 Designation (Depart-
ment of Veterans Affairs 2017). Priority Group 1 patients have severe service-
connected disabilities. Most other VA patients paid $8 a month for each
cholesterol medication they received during our study period. We restricted
our sample to patients not liable for a VA copayment for two reasons. First, by
excluding patients who faced VA copayments, we were better able isolate the
effect on provider behavior of the formulary change. Second, because we
could not account for medications prescribed outside the VA, this exclusion
minimized any bias introduced by increases in patients seeking prescriptions
from low-cost generic programs (e.g., $4 generic medications at some pharma-
cies) or other non-VA pharmacies. We also excluded patients under 40 years
of age and over 75 years of age in each month because most risk calculators
are not valid for these groups. Finally, we excluded any patients with a record
of pregnancy, end-stage renal disease, or documented muscle weakness in the
2 years prior to start of each month. Further details regarding cohort creation
are described in Section A1 of Appendix SA2.
Outcomes
Our main outcome of interest, which was based directly on the ACC/AHA
guidelines (Stone et al. 2014a), was prescription of a moderate-to-high-inten-
sity statin among high-risk patients. Table S1 of Appendix SA2 provides addi-
tional details on how we defined low-, moderate-, and high-intensity statins by
active ingredient and dosage. We defined high risk as belonging to one of four
high-risk groups: (1) atherosclerotic cardiovascular disease (ASCVD); (2)
hyperlipidemia; (3) diabetes; or (4) 10-year calculated ASCVD risk ≥7.5 per-
cent. Because the VA allows a maximum 90-day prescription for statins and
most (78 percent) patients receive a 90-day prescription, we defined a patient
as being on a statin if we observed a prescription in the 90 days prior to the
end of the month of interest (i.e., 90-day look-back). We categorized patient-
risk groups according to the ACC/AHA guidelines and in the following hier-
archical, mutually exclusive manner. The ASCVD group comprised patients
with history of myocardial infraction, coronary artery bypass grafting, percu-
taneous coronary intervention, or ischemic vascular disease. The hyperlipi-
demia group included patients with no ASCVD and low-density lipoprotein
(LDL) ≥190 mg/dL. The diabetes group included patients with no ASCVD,
LDL between 70 and 189 mg/dL, and diabetes mellitus. The group with 10-
year calculated ASCVD risk ≥7.5 percent included patients with no ASCVD,
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no diabetes, LDL between 70 and 189 mg/dL, and a 10-year ASCVD risk
≥7.5 percent as defined by the ACC/AHA ASCVD risk calculator (available
at http://tools.acc.org/ASCVD-Risk-Estimator/). The ASCVD risk score is a
function of age, gender, race (black vs. nonblack), diabetes status, smoking sta-
tus, systolic blood pressure, treatment for hypertension, LDL, and total
cholesterol levels. Any patient who did not fall into one of four high-risk
groups was considered low risk. The ACC/AHA guidelines did not specify
whether low-risk patients should be on a statin and instead called for shared
decision making based on factors such as family history of ASCVD. Sec-
tion A3 of Appendix SA2 provides further details on how we defined the four
high-risk groups.
To better understand the effects of changes to formulary and guideline
policies, we assessed outcomes specific to each policy as well as those shared
by the policies. First, we evaluated monthly changes in the prescription of sta-
tin drugs that were added to (atorvastatin), always on (simvastatin, pravas-
tatin), or never on (rosuvastatin) the VA formulary during our study period
(Veterans Health Administration 2012). Second, we evaluated changes in the
prescription of nonstatin lipid-lowering drugs (listed in Section A2 of the
Appendix SA2), as these were not directly affected by the formulary change
but were reduced in importance by the ACC/AHA guideline. The new guide-
line shifted from recommending lowering LDL levels to specified goals (re-
gardless of whether statins or nonstatins were used to lower LDL levels) and
toward recommending lowering cardiovascular risk through the use of evi-
dence-based statin drugs. Third, we evaluated monthly changes in the pre-
scription of specific moderate-to-high-intensity statins as defined by dosage
(Table S1 in Appendix SA2) that were either added to (atorvastatin), always
on (simvastatin, pravastatin), or never on (rosuvastatin) the VA formulary dur-
ing our study period, as prescription of these drugs captures the joint effects of
the formulary and guideline changes. Although we included all moderate-to-
high-intensity statin drugs in our main analysis, we only analyzed changes to
specific statin drugs that were prescribed to at least 5 percent of patients over
the study period, on average. This excluded fluvastatin (3 percent), lovastatin
(1 percent), and pitavastatin (<1 percent).
Exposure
We used an interrupted time-series approach, which estimates the effects of an
interruption that occurs at a specific moment in time, or, in our analysis, two
interruptions—October 12, 2012, when atorvastatin was added to the VA
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formulary, and November 12, 2013, when the new ACC/AHA cholesterol
guidelines were published online in the journals Circulation and Journal of
the American College of Cardiology (Stone et al. 2014a, b). We divided our
study into three periods: preformulary ( July 2011–September 2012); post-
formulary (October 2012–October 2013); and postguideline (November
2013–June 2016). We defined the postformulary and postguideline periods
as beginning in October 2012 and November 2013, respectively, so as to
capture any immediate responses that occurred. We validated our choice
of the postformulary period through analysis of historical VA documents
(Veterans Health Administration 2012). We validated our choice of the
postguideline period by a series of Google trend analytics searches, all of
which demonstrated an immediate, sharp increase in query volume
between November 10 through November 23, 2013, for the terms “choles-
terol guideline,” “statin,” “statin cholesterol,” and “cholesterol risk calcula-
tor” (Figure S1, Panels A–D in Appendix SA2). Interest in the cholesterol
guidelines was partially sustained (Figure S1, Panel A in Appendix SA2).
This was in the setting of already increased interest in simvastatin after the
FDA issued a June 2011 black box warning that simvastatin might cause
an increased rate of myopathy (see “simvastatin” query results in
Figure S1, Panel E in Appendix SA2).
Statistical Analysis
We first compared the characteristics of patients in the final months of the pre-
formulary (September 2012), postformulary (October 2013), and postguide-
line ( June 2016) periods. We then performed interrupted time-series analyses
to assess the sequential impact of the 2012 formulary change and 2013 ACC/
AHA guideline change. We used patient-level generalized estimating equa-
tion (GEE) models and included a binomial distribution and a log link func-
tion to account for the binary nature of our outcomes (Ballinger 2004). We
estimated GEE models for the following outcomes: (1) the use of any moder-
ate-to-high-intensity statin among high-risk patients; (2) the use of nonstatin
lipid-lowering drugs among all patients; and (3) the use of specific moderate-
to-high-intensity statin drugs, including atorvastatin, simvastatin, pravastatin,
and rosuvastatin, among all patients.
We modeled changes in statin prescribing across the two policy changes
using a linear term for time as well as linear splines for the preformulary, post-
formulary, and postguideline periods. This allowed us to estimate how trends
in statin prescribing changed after the formulary change and after the
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guideline change (Kontopantelis et al. 2015). In all analyses, we accounted for
possible changes in the composition of VA patients over time by adjusting for
patient-level covariates. These included patient age, gender, race, diabetes sta-
tus, and comorbidity (Charlson score). We also included indicators for each
month to account for possible seasonal changes in statin prescribing patterns
(Bhaskaran et al. 2013).
Next, we conducted counterfactual analyses for each model to compare
the predicted use of statins with the observed use of statin in both the postfor-
mulary and postguideline periods. We calculated the effect of the formulary
change on statin prescribing in the following three steps: (1) estimated trends
in statin prescribing in the preformulary period ( July 2011–September
2012); (2) used preformulary trends to estimate the expected percentage of
patients using statins at the end of the postformulary period (October 2013),
had the formulary change not occurred; (3) estimated the difference between
the predicted and observed percentage of patients using statins, that is, the
marginal effect of the formulary change. We performed a similar
counterfactual analysis to calculate the effect of the guideline change on sta-
tin prescribing, now using trends estimated in the postformulary period
(October 2012–October 2013) rather than preformulary period to estimate
expected versus observed statin prescribing, that is, the marginal effect of
the guideline change. Because the postguideline period was nearly 2 years
longer than the postformulary period, we estimated the expected use of sta-
tins at the midway point rather than endpoint of the postguideline period
(i.e., February 2015) to compare more fairly the effects of the formulary and
guideline change (Kontopantelis et al. 2015).
We next assessed changes in prescribing of specific statin drugs (i.e., ator-
vastatin, simvastatin, rosuvastatin, and pravastatin) graphically. We plotted
unadjusted trends in the use of specific statin drugs across all patients as well as
stratified by the five patient groups (i.e., ASCVD, hyperlipidemia, diabetes,
10-year calculated ASCVD risk ≥7.5 percent, and low-risk). We described
changes for prescribing of specific statins at any intensity as well as across low,
moderate, and high intensities.
Sensitivity Analyses
We performed sensitivity analyses to examine whether the effects of the two
policy changes varied across important patient subgroups. Because the 2013
ACC/AHA guidelines recommend statins to certain patient populations that
would not have required statins under the 2004 guidelines (i.e., patients with
2002 HSR: Health Services Research 52:6, Part I (December 2017)
high 10-year calculated ASCVD risk), we hypothesized that the effect of the
guidelines on statin prescribing might vary across the four ACC/AHA high-
risk groups (ASCVD, hyperlipidemia, diabetes, 10-year calculated ASCVD
risk ≥7.5 percent). To test this, we evaluated variation in the effects of the for-
mulary and guideline changes on use of moderate-to-high-intensity statins by
estimating a GEE model in which we fully interacted indicators for the three-
time periods (preformulary, postformulary, postguideline) with indicators for
the four risk groups.
Finally, we assessed whether prescribing responses to the formulary
changes and the guideline changes varied across newly high-risk patients
(“incident”) versus those who had been already been high risk for at least
6 months (“prevalent”). We defined incident patients as those with at least
one diagnostic code for either ASCVD or diabetes within the 6 months
prior to the month of interest, but none prior to that 6-month period. We
defined prevalent patients as those with at least one diagnostic code for
either ASCVD or diabetes prior to that 6-month period. To ensure that we
captured disease incidence prior to the start of the study ( July 1, 2011), we
began our look-back for all patients in July 1, 2009. We performed this
analysis for two reasons. First, we hypothesized that providers may be
more responsive to formulary or guideline changes for incident patients
than for prevalent patients, for whom clinical decisions have already been
made. Second, we hypothesized that the two policies’ specific sequence—
namely, that the guideline change followed the formulary change—might
affect our estimates of the guideline’s effect on statin prescribing (i.e.,
“order effects”), as providers may have already changed care in response to
the formulary change before the guidelines change occurred. If this were
the case, these effects should be minimized in incident high-risk patients
who should have not been affected by the formulary change. To test this,
we estimated interaction models that examined whether the effects of the
guideline or formulary changes differed across incident versus prevalent
patients.
We considered p values of <.05 to be significant. We specified GEE
models to include an exchangeable working correlation matrix and
robust standard errors to account for within-patient correlation over
time. All analyses were conducted in Stata, version 14.1. This study was
supported as an internal, nonresearch activity under a Memorandum of
Understanding with the VA Office of Reporting, Analytics, Performance
Improvement and Deployment (RAPID) to improve quality of care at
the VA.
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RESULTS
We identified 1,100,682 active primary care patients (representing 36,818,121
patient-months or 33.5 months per patient), ages 40–75, who sought care in
the VA from July 1, 2011, to June 30, 2016, and were in priority group 1 and
thus exempt from drug copayments. Table 1 summarizes changes in patient
characteristics over the study period. The mean age (SD) was 60.5 (8.0) in the
preformulary period and 61.7 (9.2) in the postguideline period (p < .001). The
share of patients belonging to one of four high-risk groups fell from 89.3 per-
cent in the preformulary period to 86.9 percent in the postguideline period
(p < .001). This was driven by a decline in the share of patients with history of
ASCVD from 47.1 to 43.1 percent in the preformulary and postguideline peri-
ods, respectively (p < .001).
Figure 1 displays estimated trends in prescribing of moderate-
to-high-intensity statins among high-risk patients, that is, those with
ASCVD, diabetes, hyperlipidemia, or a 10-year calculated ASCVD risk
≥7.5 percent. Prescribing of moderate-to-high-intensity statin fell in the pre-
formulary period (change in percentage of patients on a statin per month,
0.2 percentage point [pp] per month, 95% confidence interval [CI], 0.2
to 0.2; p < .001), leveled off in the postformulary period (0.0 pp per
month, 95% CI, 0.0 to 0.0; p < .001), and remained relatively flat in the
postguideline period (0.0 pp per month, 95% CI, 0.0 to 0.0; p < .001; Fig-
ure 1 and Table 2).
The formulary change was associated with approximately a 2 percent-
age-point increase in the use of moderate-to-high-intensity statins (marginal
effect [ME], 2.4 pp, 95% CI, 2.1 to 2.6; p < .001) compared to what would
have been expected from trends prior to the change. The guideline change
was associated with a less than 1 percentage-point increase in the use of mod-
erate-to-high-intensity statins (ME, 0.8 pp, 95% CI, 0.6 to 0.9; p < .001).
We next assessed the prescribing behaviors we considered directly rele-
vant to the formulary change (the use of specific statin drugs), the guideline
change (the use of nonstatin lipid-lowering drugs), or both (the use of specific
moderate-to-high-intensity statins).
Figure 2 demonstrates trends in the use of specific statin drugs that were
added to (atorvastatin), always on (simvastatin, pravastatin), or never on (rosu-
vastatin) the VA formulary during our study period. We observed a large sub-
stitution away from prescribing simvastatin and rosuvastatin and toward
prescribing atorvastatin. The substitution in prescribing occurred across all
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subgroups but was greatest for patients with ASCVD and least for low-risk
patients. The proportion of VA patients prescribed atorvastatin increased
from 0.5 percent in the preformulary period ( July 2011) to 13.5 percent in the
postformulary period (October 2013), and then to 22.5 percent in the post-
guideline period ( June 2016). Conversely, simvastatin prescribing declined
steadily throughout the study period, falling from 32.2 percent ( July 2011) to
12.8 percent ( June 2016). Finally, both rosuvastatin and pravastatin increased
in the preformulary period, fell in the postformulary period, and stabilized in
the postguideline period. In supplemental analyses, we found that substitution
away from simvastatin and rosuvastatin and toward atorvastatin was greatest
Table 1: Characteristics of Patients in the Veterans Affairs before and after
Formulary and Guideline Changes (2011–2016;N = 1,100,682)
Characteristic
Across the Three Study Periods
p Value
Preformulary Postformulary Postguideline
September 2012 October 2013 June 2016
Age, mean (SD) 60.5 (8.0) 61.1 (8.3) 61.7 (9.2) <.001
Female 7.0 7.4 8.6 <.001
Black 22.2 22.5 23.4 <.001
Smoker 26.5 25.9 23.3 <.001
Diabetes 41.0 40.7 39.3 <.001
Charlson score, mean (SD) 1.0 (1.5) 1.0 (1.5) 1.1 (1.6) <.001
ACC/AHA risk group
High-risk 89.3 88.9 86.9 <.001
ASCVD 47.1 46.0 43.1
Hyperlipidemia 3.1 3.4 3.4
Diabetes 18.6 18.8 18.8
10-year calculated risk ≥7.5% 20.4 20.7 21.6
Low-risk (10-year calculated risk <7.5%) 10.7 11.1 13.1
10-year calculated ASCVD risk
<7.5% 18.0 18.1 20.0 <.001
7.5% to <12% 13.7 12.5 10.9
≥12% 68.3 69.4 69.1
Most recent LDL in past year (mg/dL)
<100 48.7 48.8 45.6 <.001
100–129 20.9 21.0 21.1
130–189 12.8 12.8 14.3
≥190 1.1 1.0 1.3
No LDLmeasurement 16.5 16.3 17.7
Note. All estimates are reported in percent unless otherwise indicated. Characteristics as defined in
text and Appendix SA2.
ASCVD, atherosclerotic cardiovascular disease; LDL, low-density lipoprotein; SD, standard
deviation.
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for high-intensity statins and least for low-intensity statins (Figure S2 in
Appendix SA2).
We then assessed the joint influence of the formulary and guideline
changes by modeling changes in the use of specific moderate-to-high-intensity
statin drugs (Table 2). These estimates confirmed our graphical analyses in
Figure 2 and Figure S2 in Appendix SA2: the addition of atorvastatin to the
formulary was associated with a nearly 12 percentage-point increase in the use
of moderate-to-high-intensity atorvastatin (ME, 11.5 pp, 95% CI, 11.3 to 11.6;
p < .001; Table 2). Conversely, the use of moderate-to-high-intensity rosuvas-
tatin fell by nearly 9 percentage-points following the formulary change (ME,
8.8 pp, 95% CI, 8.8 to 8.9; p < .001; Table 2). Meanwhile, the secular
decrease in the use of moderate-to-high-intensity simvastatin that predated the
formulary change was not substantially affected by either the formulary or
guideline change (Table 2).
Prescribing of nonstatin lipid-lowering drugs, the use of which the
ACC/AHA guidelines deemphasized, was not substantially affected by either
the formulary or guideline change (Table 2). Prescribing of nonstatin lipid-
lowering drugs fell in the preformulary period (change in percentage of
patients on a statin per month, 0.2 pp per month, 95% CI, 0.2 to 0.2;
p < .001), fell more slowly in the postformulary period (0.1 pp per month,
95% CI, 0.1 to 0.1; p < .001), and then again fell more quickly in the
Figure 1: Changes in Prescribing of Moderate-to-High-Intensity Statins
among High-Risk Patients in the Veterans Affairs (2011–2016) [Color figure
can be viewed at wileyonlinelibrary.com]
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postguideline period (0.2 pp per month, 95% CI,0.2 to0.2; p < .001). In
counterfactual analyses, neither the formulary nor the guideline change was
associated with substantial changes in the prescription of nonstatin lipid-
lowering drugs (ME, 0.4 pp, 95% CI, 0.3 to 0.5; p < .001 and ME, 0.8 pp,
95% CI,0.8 to0.7; p < .001, respectively).
Changes in prescribing of moderate-to-high-intensity statins were simi-
lar across the four patient-risk groups (Table 2). The formulary change was
associated with approximately a 2 percentage-point increase in the use of
moderate-to-high-intensity statins for patients with either ASCVD (ME,
2.4 pp, 95% CI, 2.1 to 2.6; p < .001) or 10-year calculated ASCVD risk ≥7.5
percent (ME, 2.3 pp, 95% CI, 2.0 to 2.6; p < .001) and a 3 percentage-point
increase for patients with diabetes (ME, 3.0 pp, 95% CI, 2.6 to 3.4; p < .001).
The guideline change was associated with a slightly less than 1 percentage-
point increase in the use of moderate-to-high-intensity statins for patients with
Figure 2: Trends in Prescribing of Specific Statin Drugs in the Veterans
Affairs, by ACC/AHA Risk Group (2011–2016) [Color figure can be viewed
at wileyonlinelibrary.com]
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ASCVD, hyperlipidemia, diabetes, or 10-year calculated ASCVD risk ≥7.5
percent.
Finally, we found that the effects of the formulary and guideline changes
had similar effects across incident and prevalent high-risk patients (Table 2).
Following the formulary change, the use of moderate-to-high-intensity statins
increased by approximately 3 versus 2 percentage points in incident versus
prevalent patients (ME, 3.4 pp, 95% CI, 2.7 to 4.2; p < .001 and ME, 2.4 pp,
95% CI, 2.2 to 3.4; p < .001, respectively). As in our main analysis, we
observed little change in the use of moderate-to-high-intensity statins among
either incident or prevalent high-risk patients following the guideline change
(ME, 0.6, 95% CI, 1.3 to 0.1; p = .090 and ME, 0.8, 95% CI, 0.6 to 0.9;
p < .001, respectively).
DISCUSSION
We studied the sequential effects of two policy changes—the addition of a
high-potency statin to the VA formulary in 2012 and the release of the national
cholesterol treatment guidelines in 2013—on provider prescribing behavior
in the VA health care system. We found that the formulary change dramati-
cally altered statin prescribing, increasing the use of atorvastatin and decreas-
ing the use of statins that were either lower-potency or off-formulary.
Conversely, we found that the use of moderate-to-high-intensity statins among
high-risk patients, the primary goal of the new ACC/AHA guidelines, was not
substantially affected by either the formulary or guideline change. In fact, the
change in the VA formulary was associated with slightly larger effects than the
guideline change, despite predating it, a finding likely driven by the increased
availability of higher potency atorvastatin. We observed these patterns across
all high-risk groups and among both incident and prevalent high-risk patients.
Collectively, our findings suggest that an administrative change to the VA for-
mulary, simply by making a more potent statin readily available, had a greater
effect on moderate-to-high-intensity prescribing than the release of a guideline
specifically intended to extend such prescribing across high-risk patients.
The effects of formulary changes and other administrative policies are
often difficult to assess due to the fragmented nature of health care financing
and delivery (Shrank et al. 2004). Previous studies of formulary restrictions,
particularly those in which patients faced “tiered” copayments that vary
according to formulary coverage, found that formularies significantly affected
provider prescribing and patient adherence (e.g., Leibowitz, Manning, and
2010 HSR: Health Services Research 52:6, Part I (December 2017)
Newhouse 1985; Shrank and Hoang 2006). By performing this analysis in a
setting with no tiered copayments and among patients who have no medica-
tion copayment, we isolated formularies’ effects on providers specifically.
Thus, the very large substitutions that we observed toward atorvastatin and
away from simvastatin and rosuvastatin presumably resulted from the fact that
providers could now prescribe atorvastatin—a more potent drug than what
was previously available on formulary—with greater ease and without need-
ing to request it through nonformulary consultations. Our results are consis-
tent with some previous studies showing that the VA’s formulary system has
the potential to significantly affect prescription drug use (Huskamp, Epstein,
and Blumenthal 2003; Gellad et al. 2013). Similarly, the large decline in use of
simvastatin during the preformulary period, though not a central focus of our
analysis, is temporally associated with the FDA’s June 2011 “black box” warn-
ing regarding use of high-dose simvastatin (Food and Drug Administration
2011), a finding consistent with some studies of previous drug-specific FDA
regulatory warnings (Dorsey et al. 2010; Dusetzina et al. 2012).
Themodest effect of the ACC/AHA guideline change on statin prescrib-
ing we observed is consistent with some recent reports that the ACC/AHA
guideline change was associated with either a negligible (Tran et al. 2016) or
small (Rodriguez et al. 2016; Pokharel et al. 2017) change in the use of statins
and nonstatin lipid-lowering drugs. A study in the VA found somewhat larger
changes in statin use but did not include all high-risk patients, was limited to
6 months of postguideline data, and did not adjust for underlying trends in sta-
tin use (Rodriguez et al. 2016). In a large national cardiology outpatient reg-
istry, the guideline change was associated with a modest increase in the use of
moderate-to-high-intensity statins among high-risk patients (Pokharel et al.
2017). We extend and contextualize these prior results, finding that an admin-
istrative change designed to substitute one statin for another had a greater inci-
dental effect on guideline-concordant prescribing of moderate-to-high-
intensity statins than the release of the ACC/AHA guideline itself.
Nonetheless, overall use of moderate-to-high-dose statins remains sub-
stantially lower than recommended by the guidelines, and there is no evidence
of increased use in the ASCVD group for whom the benefits are felt to be the
largest. Furthermore, our finding that the guideline’s effect was similar
between incident and prevalent high-risk patients suggests that its minimal
impact held true among patients for whom clinical decisions had not yet been
made and was not entirely due to the fact that the guideline change occurred
after the formulary change. These low levels of statin use appear similarly
unresponsive to changes in performance measurement, with little change in
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statin use among high-risk patients following the VA’s FY2016 transition from
HEDIS measures focused on cholesterol levels (i.e., annual hyperlipidemia
screening among patients with cardiovascular disease) to measures focused on
treating cardiovascular risk (e.g., the use of statins among patients with dia-
betes or cardiovascular disease).
There are several limitations to consider. First, the quasi-experimental
design of our study makes it difficult to be sure that changes in prescribing
behavior were caused by changes to the VA formulary or ACC/AHA guide-
line. While the speed with which atorvastatin replaced simvastatin and rosu-
vastatin strongly suggests that the formulary change is the primary cause of
that change, we cannot verify that the use moderate-to-high-intensity statins
would have continued to decline in the postformulary period in the absence of
the formulary change. Likewise, the finding that the guideline change led to a
large decrease in atorvastatin prescribing is contingent on the assumption that
the dramatic postformulary atorvastatin increase would have continued una-
bated in the postguideline period. Second, we do not have information about
patient refusal to take statins or whether patients experienced muscle pain or
other side effects of treatment that might explain why some patients eligible
for treatment are not getting it. Third, our 90-day look-back approach may
miss some statin refills for patients with imperfect adherence or who have
accumulated medicine beyond the maximum 90-day statin prescription
length. However, most VA patients receive 90-day statin prescriptions, and a
longer look-back period would have captured patients who had actually
stopped statin use and made it more difficult to precisely detect monthly
changes in prescribing behavior.
Fourth, because we could not account for medications prescribed out-
side the VA, we limited our sample to Priority Group 1 patients who are
statutorily copayment-exempt in the VA and thus less likely to purchase sta-
tins outside the VA. Although we developed and chose this method to limit
the bias that would be induced by an increase in the use of very low-cost gen-
eric medicines and other non-VA pharmacies over time, our results may not
generalize to patients with higher incomes or lower levels of disability (i.e.,
priority groups 2–8). Finally, the effect of formularies and other administra-
tive policies is likely context specific and may not generalize outside of a
large, integrated system such as the VA. At the same time, using data from
the VA, the largest integrated health care system in the United States, offered
a rare opportunity to examine how provider behavior is affected by adminis-
trative policies that are typically fragmented across payers and otherwise dif-
ficult to observe.
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Overall, our study provides new evidence on the influence of guideli-
nes and administrative policies on provider behavior. Relevant to payers
and health care systems, our results suggest that lowering administrative
barriers to substitute drugs that providers perceive as superior can have sub-
stantial effects on quality of care. For guideline developers, our results sug-
gest that even a “best case” clinical practice guideline—that comes from a
particularly prominent group, simplifies treatment, and generates wide-
spread attention—may nonetheless exert limited influence on providers.
This reflects, in part, the fact that guidelines are intended to shape and not
compel provider behavior. And for both policy makers and health services
researchers, we demonstrate that subtle changes to pervasive administrative
policies may have large incidental consequences that should be both antici-
pated and searched for when evaluating other, seemingly unrelated health
policies.
Our collective findings suggest that certain formulary policies may influ-
ence provider prescribing behavior more than clinical practice guidelines.
Moving forward, research in this area should focus on how formularies and
other administrative policies can be used to support adherence to clinical prac-
tice guidelines and complement other policies intended to promote the quality
and efficiency of prescribing behavior.
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